替尔泊肽对阻塞性睡眠呼吸暂停合并肥胖患者的临床影响
基于TriNetX全球协作网络数据的回顾性队列研究,纳入2022年1月至2024年11月期间成人OSA合并肥胖患者,经倾向性评分匹配后比较替尔泊肽组与生活方式干预组各21,150例。替尔泊肽与较低的全因死亡、主要不良心血管事件及主要不良肾脏事件风险相关,各年龄、性别、BMI和CPAP使用亚组(18-39岁组除外)结果一致。
要点
- 替尔泊肽与OSA合并肥胖患者全因死亡风险降低相关(HR 0.443)。
- 替尔泊肽与MACE风险降低(HR 0.731)及MAKE风险降低(HR 0.427)相关。
- 除18-39岁亚组外,年龄、性别、BMI和CPAP使用各亚组结果一致。
核心结论
- 替尔泊肽可能与OSA合并肥胖患者全因死亡、心血管事件及肾脏相关并发症风险降低相关。
- 替尔泊肽可能是改善该人群临床结局的潜在治疗选择。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球协作网络数据。
- 纳入2022年1月1日至2024年11月30日期间成人OSA合并肥胖患者。
- 分为替尔泊肽处方组与生活方式干预对照组,采用倾向性评分匹配平衡协变量。
- 匹配后共纳入42,300例患者,每组21,150例。
主要发现
- 替尔泊肽组全因死亡风险较低(HR 0.443,95%CI 0.336-0.583)。
- 替尔泊肽组MACE风险降低(HR 0.731,95%CI 0.622-0.859)。
- 替尔泊肽组MAKE风险降低(HR 0.427,95%CI 0.343-0.530)。
- 除18-39岁亚组外,按年龄、性别、BMI和CPAP使用分层的其他亚组关联一致。
- 敏感性分析支持结果的稳健性。
临床怎么用
- 在OSA合并肥胖患者中,可考虑替尔泊肽作为改善临床结局的潜在治疗选择。
- 临床决策时应结合患者年龄、BMI及CPAP使用情况综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: OSA is a prevalent chronic condition linked to obesity that is associated with increased risks of cardiovascular and kidney disease. Although weight loss can improve OSA outcomes, additional effective therapeutic options are needed. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has shown promise in promoting significant weight loss and reducing OSA severity. RESEARCH QUESTION: Does tirzepatide affect clinical outcomes in individuals with OSA and obesity? STUDY DESIGN AND METHODS: This study was conducted using the TriNetX Global Collaborative Network and included adults with OSA and obesity between January 1, 2022, and November 30, 2024. Patients were divided into 2 groups: those prescribed tirzepatide (study group) and those receiving lifestyle interventions (control group). Propensity score matching (PSM) was applied to balance covariates. The primary outcome was all-cause mortality, with secondary outcomes including major adverse cardiovascular events (MACEs) and major adverse kidney events (MAKEs). RESULTS: After PSM, the study included 42,300 patients (21,150 patients in each group). The tirzepatide group was associated with a lower risk of all-cause mortality (hazard ratio [HR], 0.443 [95% CI, 0.336-0.583]). Tirzepatide use also was associated with reduced risks of MACEs (HR, 0.731 [95% CI, 0.622-0.859]) and MAKEs (HR, 0.427 [95% CI, 0.343-0.530]). Except for the group 18 to 39 years of age, these associations remained consistent across all other subgroups when stratified by age, sex, BMI, and CPAP use. Sensitivity analyses supported the robustness of these findings. INTERPRETATION: Tirzepatide could be associated with reduced mortality, cardiovascular events, and kidney-related complications in patients with OSA and obesity. These findings suggest that tirzepatide may be a potential therapeutic option for improving clinical outcomes in this population.
引用
- Wu JY, Chen CC, Ling Tu W, et al. Clinical Impact of Tirzepatide on Patients With OSA and Obesity. Chest. 2025. PMID: 40254150. doi:10.1016/j.chest.2025.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。